CHRS aims to achieve $15M in quarterly LOQTORZI sales by early 2026, leveraging its role in nasopharyngeal cancer treatment.
Coherus BioSciences targets $15M in quarterly sales for its LOQTORZI therapy by Q1 2026, positioning the drug as a key revenue driver in nasopharyngeal cancer (NPC). Management highlighted LOQTORZI’s dual role as both a standalone treatment and a combination therapy with pipeline candidates tagmokitug and casdozokitug, expected to enhance its market potential.
The company’s strategy follows recent advancements in its oncology pipeline, with midyear readouts anticipated for tagmokitug and casdozokitug. LOQTORZI’s projected peak share in NPC underpins the revenue outlook, though specific market penetration details remain undisclosed.
No immediate market reaction was reported following the earnings call insights.